Immunoadsorption

From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history

Immunoadsorption or IA is an the technique by which immunoglobulins, especially undesirable antibodies, are removed from blood plasma. Repeat Immunoadsorption or RIA involves a series of immunoadsorption treatments at fixed intervals.[1] Immonoadsorption is an apheresis treatment which has been investigated for ME/CFS and Long COVID patients.[2][1]

Theory[edit | edit source]

A number of studies have found that a subset of ME/CFS patients have abnormal autoantibodies in their blood; immunoadsorption could be used to remove these autoantibodies with the aim of improving symptoms or potentially curing ME/CFS in those patients.[2]

Evidence[edit | edit source]

A pilot study published before peer-review found Repeat Immunoadsorption was effective in improving ME/CFS symptoms in 10 patients with Long COVID who met the Canadian Consensus Criteria for ME/CFS, after developing ME/CFS after COVID-19 infection.[1]

Notable studies[edit | edit source]

  • 2023, Observational Study of Repeat Immunoadsorption (RIA) in Post-COVID ME/CFS Patients with Elevated Beta-2-Adrenergic Receptor Autoantibodies[1] - (Preprint - Full text)
  • 2018, Immunoadsorption to remove ß2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME[2] (Full Text)

Clinicians[edit | edit source]

Risks and safety[edit | edit source]

Immunoadsorption is considered to have fewer adverse effects than the use of therapeutic plasma exchange.[3] Several medical conditions, such as multiple sclerosis[4] and chronic inflammatory demyelinating polyneuropathy (CIDP) may use immunoadsorption as part of their medical regimen.[5]

Costs and availability[edit | edit source]

Learn more[edit | edit source]

See also[edit | edit source]

References[edit | edit source]

  1. ↑ 1.0 1.1 1.2 1.3 Stein, Elisa; Heindrich, Cornelia; Wittke, Kirsten; Kedor, Claudia; Kim, Laura; Freitag, Helma; Krueger, Anne; Toelle, Markus; Scheibenbogen, Carmen (September 1, 2023). "Observational Study of Repeat Immunoadsorption (RIA) in Post-COVID ME/CFS Patients with Elevated Beta-2-Adrenergic Receptor Autoantibodies". medrxiv: 2023.08.31.23294813. doi:10.1101/2023.08.31.23294813.
  2. ↑ 2.0 2.1 2.2 Scheibenbogen, Carmen; Loebel, Madlen; Freitag, Helma; Krueger, Anne; Bauer, Sandra; Antelmann, Michaela; Doehner, Wolfram; Scherbakov, Nadja; Heidecke, Harald (March 15, 2018). "Immunoadsorption to remove ß2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME". PLOS ONE. 13 (3): e0193672. doi:10.1371/journal.pone.0193672. ISSN 1932-6203. PMC 5854315. PMID 29543914.
  3. ↑ Pham, H.P.; Schwartz, J. (2013). "79 - Immunoadsorption". In Shaz, B. H.; Hillyer, C.D. (eds.). Transfusion medicine and hemostasis: clinical and laboratory aspects (2 ed.). Newnes. pp. 525–527. doi:10.1016/B978-0-12-397164-7.00079-3.
  4. ↑ Koziolek, Michael J.; Tampe, Desiree; Bähr, Matthias; Dihazi, Hassan; Jung, Klaus; Fitzner, Dirk; Klingel, Reinhard; Müller, Gerhard A.; Kitze, Bernd (April 26, 2012). "Immunoadsorption therapy in patients with multiple sclerosis with steroid-refractory optical neuritis". Journal of Neuroinflammation. 9 (1): 80. doi:10.1186/1742-2094-9-80. ISSN 1742-2094. PMC 3418188. PMID 22537481.
  5. ↑ Lehmann, Helmar C.; Hughes, Richard A.C.; Hartung, Hans-Peter (January 1, 2013). "23 - Treatment of chronic inflammatory demyelinating polyradiculoneuropathy". In Said, Gérard; Krarup, Christian (eds.). Handbook of Clinical Neurology. Peripheral Nerve Disorders. 3. 115. Elsevier. pp. 415–427. doi:10.1016/b978-0-444-52902-2.00023-0.
Retrieved from "https://me-pedia.org/w/index.php?title=Immunoadsorption&oldid=241752"